INMB News and Press, INmune Bio Inc. From 04/19/23

TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™ Boca Raton, Florida, April 19, 2023 (GLOBE NEWSWIRE) -- INmune Bio, In...

Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy "Emerging Targeted Therapies for HER2-Positive Breast Cancer" has been published in Cancers as part of a special issue on Targe...

2023-04-03 10:48:24 ET INmune Bio ( NASDAQ: INMB ) is trading ~7% higher after it had submitted an investigational new drug application to the U.S. Food and Drug Administration (FDA) for INKmune to treat metastatic castration-resistant prostate cancer. The 6-mont...

BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that...

INmune Bio, Inc. (INMB) Q4 2022 Earnings Conference Call March 2, 2023 04:30 PM ET Company Participants David Moss - CFO RJ Tesi - CEO CJ Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Jason McCarthy -...

INmune Bio press release ( NASDAQ: INMB ): FY GAAP EPS of -$1.52 beats by $0.14 . Revenue of $0.37M (+105.6% Y/Y) beats by $0.17M . As of December 31, 2022, the Company had cash and cash equivalents of approximately $52.2 million. As of March 2, 2023, the Company h...

BOCA RATON, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financi...

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Feb. 21, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient...

Clinical-stage immunology company INmune Bio ( NASDAQ: INMB ) announced Wednesday it would reinvest ~$6.4M in R&D refunds received from Australia (~$3.7M) and the U.K. (~$2.7M) in its clinical programs, including the ongoing mid-stage Alzheimer’s trial. Chief Financial Offi...

BOCA RATON, Fla., Feb. 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that it has re...